Lineage Cell Therapeutics (LCTX) Non Operating Income (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Non Operating Income of $405000.0 for Q1 2026, down 82.85% year-over-year from $2.4 million in Q1 2025, and down 81.25% quarter-over-quarter from $2.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Non Operating Income (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at $405000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 82.85% year-over-year to $405000.0; the TTM figure through Mar 2026 stood at -$22.9 million (down 551.53% YoY), while the FY2025 annual figure was -$32.0 million, down 1205.94% from the prior year.
- Non Operating Income for Q1 2026 stood at $405000.0, down from $2.2 million in the prior quarter.
- The five-year high for Non Operating Income was $2.4 million in Q1 2025, with the low at -$26.0 million in Q3 2025.
- The 5-year median for Non Operating Income is $405000.0 (2026), against an average of -$1.1 million.
- Peak annual rise in Non Operating Income reached 2193.2% in 2025, while the deepest fall reached 6640.55% in 2025.
- Lineage Cell Therapeutics' Non Operating Income stood at $277000.0 in 2022, then surged by 494.95% to $1.6 million in 2023, then increased by 12.86% to $1.9 million in 2024, then climbed by 16.13% to $2.2 million in 2025, then plunged by 81.25% to $405000.0 in 2026.
- Business Quant data shows LCTX's Non Operating Income at $405000.0 in Q1 2026, $2.2 million in Q4 2025, and -$26.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 10.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.47 Mn |
| Mar 31, 2026 | 405,000.00 |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | -25.97 Mn |
| Jun 30, 2025 | 454,000.00 |
| Mar 31, 2025 | 2.36 Mn |
| Dec 31, 2024 | 1.86 Mn |
| Sep 30, 2024 | 397,000.00 |
| Jun 30, 2024 | 463,000.00 |
| Mar 31, 2024 | 103,000.00 |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | 433,000.00 |
| Jun 30, 2023 | -179,000.00 |
| Mar 31, 2023 | 410,000.00 |
| Dec 31, 2022 | 277,000.00 |
| Sep 30, 2022 | -324,000.00 |
| Jun 30, 2022 | -2.55 Mn |
| Mar 31, 2022 | -697,000.00 |
| Dec 31, 2021 | 229,000.00 |
| Sep 30, 2021 | -2.00 Mn |